Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Empagliflozin on Cardiac and Kidney Metabolism in Type 2 Diabetes
2017-001779-22Phase 4Completed
- Sponsor
- Aarhus University Hospital
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of empagliflozin in type 2 diabetes mellitus (T2DM), sponsored by Aarhus University Hospital. Primary endpoints: Cardiac metabolic effects and Renal metabolic effects. Started May 2017; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2017-001779-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001779-22.